Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma

NCT03310567 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT03310567
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03310567 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma
Lead sponsor
Fox Chase Cancer Center
Phase
Phase 2
Overall status
Withdrawn
Start date
September 30, 2018
Completion date
September 10, 2018
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent/ metastatic endometrial carcinoma